VIVO CAPITAL LLC
Q3 2026 Form 13-F
PALO ALTO, CALIFORNIA
CIK 0001674712
· CRD 159868
· SEC-registered investment adviser
$908.7M Reported Value Total
VIVO CAPITAL, LLC reports 16 total accounts under management (AUM). There are 16 discretionary accounts valued at $6,095,582,206, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
29 funds
· $7.5B gross asset value
Private Equity Fund: $4.4B · Other: $2.2B · Venture Capital Fund: $899.0M · Securitized Asset Fund: $49.8M
Source: Form ADV filed 2026-03-31
Reported value
$908.7M
Quarter over quarter
-17.3%
Holdings
50
Top-10 concentration
51.3%
Key People
Form ADV owners & control persons
Frank Fang-Chien Kung
MANAGING PARTNER
Edgar George Engleman
MANAGING PARTNER
Shan (nmn) Fu
MANAGING PARTNER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 13, 2026 |
| Form | 13F-HR |
| Reported value | $908.7M |
| Positions | 50 |
| Change in reported value | -17.0% |
| New positions | 8 |
| Exited positions | 5 |
| Position turnover | 23.6% |
| Top-10 concentration | 51.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 13, 2026
|
50 | $908.7M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
47 | $1.1B |
|
Q1 2026 13F
Filed May 15, 2026
|
46 | $1.2B |
|
Q4 2025 13F
Filed Feb 13, 2026
|
47 | $1.5B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
47 | $1.2B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
42 | $977.1M |
|
Q1 2025 13F
Filed May 12, 2025
|
40 | $755.1M |
|
Q4 2024 13F
Filed Feb 13, 2025
|
40 | $892.6M |
|
Q3 2024 13F
Filed Nov 13, 2024
|
43 | $1.2B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
42 | $1.1B |
|
Q1 2024 13F
Filed Apr 22, 2024
|
42 | $1.3B |
|
Q4 2023 13F
Filed Feb 7, 2024
|
47 | $1.2B |
|
Q3 2023 13F
Filed Nov 8, 2023
|
53 | $912.8M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
48 | $1.4B |
|
Q1 2023 13F
Filed May 15, 2023
|
48 | $1.4B |
|
Q4 2022 13F
Filed Feb 13, 2023
|
48 | $868.5M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
51 | $905.8M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
49 | $995.9M |
|
Q1 2022 13F
Filed May 13, 2022
|
54 | $1.5B |
|
Q4 2021 13F
Filed Feb 11, 2022
|
55 | $1.7B |
23 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | PRAX Praxis Precision Medicines | $79.0M | 8.69% |
| 2 | TRVI Trevi Therapeutics Inc | $60.6M | 6.67% |
| 3 | ERAS Erasca Inc | $58.9M | 6.49% |
| 4 | AVBP Arrivent BioPharma Inc | $54.1M | 5.95% |
| 5 | ABVX Abivax SA | $41.1M | 4.52% |
| 6 | ENTX Entera Bio Ltd | $35.7M | 3.92% |
| 7 | ACRS Aclaris Therapeutics Inc | $35.2M | 3.88% |
| 8 | ANRO Alto Neuroscience Inc | $34.7M | 3.82% |
| 9 | TNGX Tango Therapeutics Inc | $34.4M | 3.79% |
| 10 | CRVS Corvus Pharmaceuticals Inc | $32.3M | 3.56% |
| 11 | LBRX LB Pharmaceuticals Inc | $30.7M | 3.38% |
| 12 | KRSA Korsana Biosciences Inc | $28.1M | 3.09% |
| 13 | BLSM Blossomhill Therapeutics Inc | $27.8M | 3.06% |
| 14 | SNSE Faeth Therapeutics Inc | $25.1M | 2.76% |
| 15 | CAMP CAMP4 Therapeutics Corporation | $22.6M | 2.48% |
| 16 | ACHV Achieve Life Science Inc | $22.3M | 2.45% |
| 17 | SABS SAB Biotherapeutics Inc | $21.9M | 2.41% |
| 18 | DBVT DBV Technologies SA | $21.7M | 2.39% |
| 19 | DRUG Bright Minds Biosciences Inc | $20.8M | 2.29% |
| 20 | DSGN Design Therapeutics Inc | $20.3M | 2.23% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.